epocrates: Drug Info & Pill ID vs MyChart
Revenue, downloads, ratings and category context for two iOS apps. Figures are estimates and should be read as ranges, not exact totals.
epocrates: Drug Info & Pill IDEpocrates - Medical
MyChartEpic - Medical| Metric | epocrates: Drug Info & Pill ID | MyChart | Readout |
|---|---|---|---|
| Estimated revenue / mo | $*** - opens with trial | $*** - opens with trial | Partial signal |
| Revenue band | $*** - opens with trial | $*** - opens with trial | Use range + confidence |
| Estimated downloads / mo | $*** - opens with trial | $*** - opens with trial | MyChart |
| Download band | $*** - opens with trial | $*** - opens with trial | Use range + confidence |
| Rating | 4.44 | 4.60 | MyChart |
| Rating count | 7.1k | 687k | MyChart |
| Tracked keywords | 1 | 2 | MyChart |
| Category | Medical | Medical | Same market |
Which app is bigger?
epocrates: Drug Info & Pill ID and MyChart are compared inside Medical with monthly revenue, downloads, rating, review volume, keyword footprint, category placement and range context. MyChart leads on monthly downloads in the current readout, while a clean revenue readout is available only for epocrates: Drug Info & Pill ID in this pair. MyChart wins demand, MyChart has deeper review volume, and MyChart has the larger tracked keyword footprint. The better app depends on the job: choose the revenue leader when you need monetization proof, choose the download leader when reach matters, and choose the higher-rated or deeper-reviewed app when market trust is the constraint. Read both ranges rather than only the midpoint, then open the category hub and related collections to see whether this pair is an outlier or a normal category pattern.